Share Repurchases and NAV Accretion
Repurchased $19.0 million of common stock in Q4 at an average discount to NAV of 18.2%, resulting in NAV accretion of approximately $0.14 per share; Board increased repurchase authorization to $60 million to continue opportunistic buybacks.
Capital-Structure Optimization
Completed full redemption of 7.75% Series B term preferred stock, announced intent to fully redeem 8% Series C preferred, and entered a new 3-year revolving credit facility with a lower cost of capital to reduce financing costs.
Strong Recurring Cash Flows and Liquidity
Recurring cash flows for Q4 were $19 million ($0.79 per share), up from $17 million ($0.67) in the prior quarter — an ~18% quarter-over-quarter increase; company had $52 million of cash and undrawn revolver capacity as of Dec 31 and $85 million of cash plus revolver capacity (net of pending transactions) as of January month-end.
Deployment into Higher-Yielding Other Credit Assets
Deployed ~$45 million into new investments in Q4, including $26 million into other credit asset classes (infrastructure credit, ABS, portfolio debt, regulatory capital relief) with a weighted average effective yield of 21.6% to enhance portfolio yields and diversification.
CLO Liability Cost Savings from Resets/Refinancings
Participated in 10 resets and 6 refinancings across the CLO equity portfolio during 2025; those transactions extended reinvestment periods and produced average CLO debt cost savings of ~46 basis points for the affected CLOs.
Market Issuance and Potential Tailwinds
CLO market activity remained robust: full-year 2025 CLO new issuance $209 billion (new issue) and combined issuance including resets/refinancings reached $546 billion, which management expects could help rebalance supply/demand and be supportive for CLO equity over time.
Increase in Expected CLO Portfolio Yield
Weighted average expected yield on the CLO portfolio rose to 12.5% from 11.6% (reported increase), driven in part by redeployment into wider-yielding non-CLO assets.